Table 1.
Subjects’ Baseline Characteristics (n=55)
| Age, Years, n | 73.49 (5.56) | 61–83 |
|---|---|---|
| Sex, male/female | 54/1 | |
| BMI, kg m−2 | 20.9 (3.2) | 14.7–25.8 |
| Cigarette smoking, pack years | 56.5 (26.5) | 11–141 |
| GOLD stage I/II/III/IV, n | 6/10/29/10 | |
| GOLD category A/B/C/D, n | 10/29/0/16 | |
| mMRC dyspnea scale 0/1/2/3/4, n | 0/10/22/12/11 | |
| Medications | ||
| LAMA, n | 53 | |
| LABA, n | 43 | |
| ICS, n | 22 | |
| Triple therapy, n | 21 | |
| Spirometry | ||
| FEV1, L | 1.24 (0.62) | 0.41–3.73 |
| % FEV1, % predicted | 47.10 (22.96) | 16.7–141.8 |
| FVC, L | 3.01 (0.89) | 1.24–5.39 |
| % FVC, % predicted | 89.4 (23.7) | 39.4–159.9 |
| FEV1/FVC, % | 40.35 (11.17) | 21.2–69.2 |
| VC, L | 3.05 (0.81) | 1.68–5.31 |
| %VC, % | 84.45 (19.73) | 48.40–146.30 |
| IC, L | 1.92 (0.52) | 0.92–3.08 |
| IRV, L | 0.96 (0.44) | 0.19–1.79 |
| ERV, L | 1.13 (0.47) | 0.33–2.85 |
| VT, L | 0.96 (0.32) | 0.29–1.77 |
Note: Data are presented as the mean (SD) and the minimum and maximum values, unless otherwise stated.
Abbreviations: BMI, body mass index; ERV, expiratory reserve volume; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; IC, inspiratory capacity; ICS, inhaled corticosteroids; IRV, inspiratory reserve volume; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; mMRC dyspnea scale, modified Medical Research Council dyspnea scale; SD, standard deviation; VC, vital capacity; VT, tidal volume.